VERA Vera Therapeutics, Inc.

Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases in the United States. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase IIb clinical trial for patients with immunoglobulin A nephropathy. The company was formerly known as Trucode Gene Repair, Inc. and changed its name to Vera Therapeutics, Inc. in April 2020. Vera Therapeutics, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.

$30.00  +3.50 (13.21%)
As of 11/26/2021 13:00:00 EST     IEX book   CBOE book


Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Small cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  USA
Country of incorporation:  USA
IPO date:  05/14/2021
Outstanding shares:  20,968,376
Average volume:  41,497
Market cap:   $555,661,964
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
CUSIP:    92337R101
ISIN:        US92337R1014
Sedol:      BL55460
Valuation   (See tab for details)
PE ratio:   0.00
PB ratio:   7.47
PS ratio:   0.00
Return on equity:   -68.60%
Net income %:   0.00%

2021 © Stock Market MBA, Inc. Terms of use | Privacy policy